← Back to Clinical Trials
Recruiting NCT06373328

NCT06373328 Post Pandemic Pneumococcal Carriage Among Children and Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06373328
Status Recruiting
Phase
Sponsor University of Central Florida
Condition Pneumococcal Carriage
Study Type OBSERVATIONAL
Enrollment 900 participants
Start Date 2024-06-12
Primary Completion 2025-09

Eligibility & Interventions

Sex All sexes
Min Age 7 Months
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 900 participants in total. It began in 2024-06-12 with a primary completion date of 2025-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The PI propose to conduct a genomic epidemiology study of pneumococcal carriage among children and adults in a large metropolitan city. These data will allow PI to assess the post-pandemic population structure, investigate the phylogenetic relationship between isolates from children and adults, and compare pneumococcal populations across diverse geographic areas.

Eligibility Criteria

Inclusion Criteria: * Children, ages 7 to 59 months (less than 5 years) * Adults, ages 50 and older * Ability to provide informed consent (from parents for children participants) * ability to read and speak in English * Agree to comply with study procedures (complete online data questionnaire and provide a nasopharyngeal collection). Exclusion Criteria: * Have been on an antibiotic in the last 2 weeks * Have a respiratory infection that would make an nasopharyngeal collection improbable * Have underlying developmental or chronic conditions impacting immune or respiratory function (e.g., immunocompromised, cystic fibrosis, cerebral palsy, paralysis) * Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.

Contact & Investigator

Central Contact

Amoy Fraser, PhD, CCRP, PMP

✉ amoy.fraser@ucf.edu

📞 4072668742

Principal Investigator

Taj Azarian, PhD

PRINCIPAL INVESTIGATOR

University of Central Florida

Frequently Asked Questions

Who can join the NCT06373328 clinical trial?

This trial is open to participants of all sexes, aged 7 Months or older, studying Pneumococcal Carriage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06373328 currently recruiting?

Yes, NCT06373328 is actively recruiting participants. Contact the research team at amoy.fraser@ucf.edu for enrollment information.

Where is the NCT06373328 trial being conducted?

This trial is being conducted at Orlando, United States.

Who is sponsoring the NCT06373328 clinical trial?

NCT06373328 is sponsored by University of Central Florida. The principal investigator is Taj Azarian, PhD at University of Central Florida. The trial plans to enroll 900 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology